January 2007December 2027
    Wild koala populations in Australia are in steep decline throughout much of their northern geographic range. Koala retrovirus (KoRV) is strongly associated with immunodeficiency and related diseases, including chlamydia.
  • Preclinical Development of a vaccine for HTLV-1

    January 2019December 2026
    Human T-lymphotropic virus type-1 (HTLV-1) is a cause of T-cell leukemia/lymphoma as well as severe autoimmune disorders. An estimated 5-10 million individuals are infected globally, with Indigenous populations in central Australia most highly affected.
  • ViceBio

    January 2019December 2024
    Keith Chappell is the Lead Scientific Advisor for Vicebio. Vicebio were founded to develop the patented Molecular Clamp technology invented at The University of Queensland, Australia and exclusively licensed to Vicebio by UniQuest, the commercialisation company of UQ.
  • Rapid Response Vaccine Pipeline

    January 2019December 2026
    The Rapid Response Vaccine Pipeline team at UQ is funded by CEPI (Coalition for Epidemic Preparedness Innovation) with a goal to develop a pipeline for rapid development of protein subunit vaccines through to Phase I Clinical trial.

Subscribe to RSS